Peer-reviewed veterinary case report
Sorafenib treatment results for dogs with advanced carcinomas
By Kim, Doyun et al.·Published in Veterinary and comparative oncology·2026·BON Animal Medical Center, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical Efficacy and Tolerability of Sorafenib in Dogs With Advanced Carcinomas.
- Species:
- dog
Plain-English summary
A group of 24 dogs with advanced cancer that couldn't be surgically removed were treated with a medication called sorafenib. After one month, 14 of the 18 dogs that could be evaluated showed stable disease, meaning their cancer wasn't getting worse. The dogs experienced some mild side effects, like lameness and stomach issues, but many gained weight, which was linked to a better response to treatment. Overall, sorafenib was found to be well tolerated and provided some benefits for dogs with serious cancer.
People also search for: dog cancer treatment sorafenib · advanced cancer in dogs · dog weight gain after treatment · lameness in dogs with cancer · prognosis for dogs with advanced carcinomas
Abstract
Advanced carcinomas in dogs present significant therapeutic challenges with limited treatment options and poor prognoses. Sorafenib, a multi-kinase inhibitor targeting RAF and receptor tyrosine kinases, has demonstrated antitumor activity and tolerability in preclinical veterinary studies; however, clinical data remain limited. This prospective, open-label cohort study evaluated the tolerability and clinical efficacy of oral sorafenib (6 mg/kg once daily) in 24 dogs with cytologically or histologically confirmed unresectable, recurrent, or metastatic carcinomas. Tumour response was assessed using RECIST criteria, and adverse events were graded according to VCOG-CTCAE v2.0. Stable disease at 1 month was observed in 14 of 18 evaluable dogs (77.8%), yielding an overall clinical benefit rate of 58.3%. Median time to progression and overall survival were 51 days (95% CI, 14-115) and 65 days (95% CI, 49-143), respectively. Dogs presenting with lameness (n = 7) showed significantly longer time to progression and overall survival than those without (p < 0.01). Adverse events occurred in 9 of 24 dogs (37.5%), primarily mild lameness (29%) and gastrointestinal signs. Weight gain at 1 month, observed in 66.7% of dogs, was significantly associated with clinical benefit (p = 0.005; OR = 45.0; 95% CI, 1.8-1127.7). Sorafenib was well tolerated and provided measurable clinical benefit in dogs with advanced carcinomas. Lameness may represent a prognostic biomarker, and weight gain may reflect a favourable clinical response. These findings support further investigation of sorafenib and other tyrosine kinase inhibitors in veterinary oncology.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41614563/